Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 30;32(6):319.
doi: 10.3390/curroncol32060319.

Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS)

Tobias Berg  1 , Brittany Salter  2 , Michael Radford  1 , He Tian Tony Chen  3 , Brian Leber  2
Affiliations
Review

Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS)

Tobias Berg et al. Curr Oncol. .

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is the sole curative therapy for myelodysplastic syndrome (MDS). While alloHCT clearly confers a significant survival advantage in high-risk MDS, it is less clear how the disease burden and impact of conditioning intensity impact survival. This review addresses critical issues surrounding this topic, emphasizing the unique cell biology of MDS and the evolving concepts of conditioning intensity compared to other diseases, including acute myeloid leukemia (AML). The review is structured around three interconnected themes. First, it clarifies the varying interpretations of conditioning intensity. Second, it examines the interplay between disease burden at transplant and conditioning intensity in determining outcomes, including a comparative analysis with acute myeloid leukemia (AML) to highlight similarities and differences. Third, it explores the relationship between conditioning regimen intensity and immune reconstitution, particularly focusing on the graft-versus-tumor (GvT) effect and its potential modulation by conditioning intensity. Understanding the stem cell target of conditioning regimens is emphasized, as the persistence of the underlying MDS stem cell necessitates a thorough understanding of this concept for improved therapeutic strategies.

Keywords: conditioning regime; myelodysplastic syndrome; transplant.

PubMed Disclaimer

Conflict of interest statement

B.S., M.R., and H.C. declare no conflicts of interest. T.B. received research funding from Imago Biosciences (a subsidiary of Merck), honoraria from AVIR Pharma, Jazz Pharmaceuticals, Bristol Myers Squibb, and Riemser Pharma GmbH, and travel funding from Incyte, Abbvie, Astellas, Alexion, and Celgene. B.L. has received honoraria for advisory board participation from Pfizer, Abbvie, Novartis, BMS/Celgene, AMGEN, Jazz, Astellas, Servier, Astex, Paladin, Alexion/Astra Zeneca, GSK, Sobi, Roche, Otsuka, Janssen, Treadwell, Forus, Medison, Takeda, and Daiichi Sankyo, and fees for consultation from Novartis, Abbvie, Pfizer, and Servier.

Figures

Figure 1
Figure 1
Transplant Conditioning Intensity (based on Spyridonis et al., 2020 [13]).
See this image and copyright information in PMC

References

    1. DeFilipp Z., Ciurea S.O., Cutler C., Robin M., Warlick E.D., Nakamura R., Brunner A.M., Dholaria B., Walker A.R., Kröger N., et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant. Cell. Ther. 2023;29:71–81. doi: 10.1016/j.jtct.2022.11.014. - DOI - PubMed
    1. Nakamura R., Saber W., Martens M.J., Ramirez A., Scott B., Oran B., Leifer E., Tamari R., Mishra A., Maziarz R.T., et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50–75 Years of Age with Advanced Myelodysplastic Syndrome. J. Clin. Oncol. 2021;39:3328–3339. doi: 10.1200/JCO.20.03380. - DOI - PMC - PubMed
    1. van Galen P., Hovestadt V., Wadsworth M.H., II, Hughes T.K., Griffin G.K., Battaglia S., Verga J.A., Stephansky J., Pastika T.J., Lombardi Story J., et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176:1265–1281.e24. doi: 10.1016/j.cell.2019.01.031. - DOI - PMC - PubMed
    1. Zeng A.G.X., Bansal S., Jin L., Mitchell A., Chen W.C., Abbas H.A., Chan-Seng-Yue M., Voisin V., van Galen P., Tierens A., et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 2022;28:1212–1223. doi: 10.1038/s41591-022-01819-x. - DOI - PubMed
    1. Pei S., Shelton I.T., Gillen A.E., Stevens B.M., Gasparetto M., Wang Y., Liu L., Liu J., Brunetti T.M., Engel K., et al. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023;13:2032–2049. doi: 10.1158/2159-8290.CD-22-1297. - DOI - PMC - PubMed

MeSH terms